There is still time to enter the PharmaTimes Marketer of the Year 2016 competition.
News
SMC green light for LEO’s Enstilar
GPs and dermatology clinicians in Scotland are now authorised to prescribe LEO Pharma’s Enstilar on the NHS for the management of all severities of plaque psoriasis in adult patients, after it was endorsed by the Scottish Medicines Consortium.
Eisai’s Kisplyx approved in EU for kidney cancer
The European Commission has stamped its approval on the use of Eisai’s Kisplyx to treat advanced kidney cancer.
Shire bags US nod for primary immunodeficiency drug
Shire’s immunology portfolio has been given a boost with US approval for Cuvitru for the treatment of primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body’s immune system is missing or failing.
FDA committee votes to pull boxed warning from Chantix
Pfizer has moved a giant leap closer to getting the strongest warning of serious neuropsychiatric events removed from the labelling of its anti-smoking drug Chantix in the US.
Roche unveils more data backing MS drug Ocrevus
Roche has released more data showing that its multiple sclerosis drug Ocrevus works better than Merck’s Rebif against the relapsing form of the disease, and also has potential in controlling the primary progressive type, bringing further hope of the first approved treatment option for this subset of patients.
NIHR streams £861m into health research projects
The government has announced a five-year funding package of £816 million for leading NHS clinicians and universities undertaking health research.
GSK files RA drug in the EU
GlaxoSmithKline has filed an application in Europe seeking approval to market its investigational human anti-interleukin (IL)-6 monoclonal antibody sirukumab for the treatment of rheumatoid arthritis (RA).
EU nod for Exelixis’ kidney cancer drug
European regulators have approved a new second-line treatment option for patients with advanced kidney cancer.
SMC clears three new drugs for NHS Scotland use
Three new medicines have been endorsed for routine use on the NHS giving patients new options for skin cancer, chronic myeloid leukaemia, and anticoagulant reversal.
Janssen files HIV combination therapy in Europe
Janssen-Cilag has submitted a marketing application to the European Medicines Agency for a new once-daily darunavir-based single tablet regimen (STR) to treat HIV.
UCB launches helpline for doctors and patients
UCB has launched of a new personalised phone service for healthcare professionals and patients that offers 24/7 advice on queries relating to UCB products.
AZ trials diabetes drug Forxiga in kidney disease, heart failure
AstraZeneca has launched two new trials with its SGLT-2 inhibitor Forxiga (dapagliflozin) exploring its potential beyond the drug’s approved diabetes indication.
GSK sells non-core assets to Aspen
GlaxoSmithKline is selling its portfolio of anaesthetics and thrombosis business to Aspen as it continues to simplify its business strategy through focusing on core therapeutic areas.
London launch for new digital accelerator scheme
DigitalHealth.London has launched its inaugural Accelerator programme, with the aim of providing “in-depth” knowledge of the NHS to a group of “high potential” small and medium digital health businesses to help narrow the gap between product develop and uptake.
